Personalized briefing
Discovery of the day · Neurology
Lecanemab use in Chinese patients with Alzheimer’s disease: a 12‐month multicenter real‐world study
Dear Kelly M Leyden, this is your personalized scientific intelligence briefing — curated for your work in Neurology.
Key finding
Medicine · Neurology
Discovery of the day
This multicenter real-world study of 1,042 Chinese patients with Alzheimer’s disease demonstrates that lecanemab treatment yields a favorable 12-month safety profile, with no clear evidence of cognitive decline observed on the Clinical Dementia Rating Scale–Sum of Boxes. Researchers found ARIA occurred in 7.87% of patients and infusion-related reactions in 16.12%, with a 16.51% discontinuation rate primarily driven by financial burden, while blood-based biomarker assays alone guided treatment in 5.28% of cases with comparable outcomes. These findings directly support your focus on clinical actionability in Alzheimer’s disease by validating that blood-based biomarkers can effectively substitute for PET or CSF assessments in real-world treatment guidance, potentially expanding access to anti-amyloid therapy through more scalable diagnostic monitoring.
Novelty
74%
Rigor
78%
Significance
76%
Validity
80%
Clarity
82%
Advertisement
GroupRFQ — join group deals on lab & medical equipment. Pool orders, unlock volume pricing. See open deals →
Your briefing is personalized based on your selected fields, keywords, and research interests.
